202 related articles for article (PubMed ID: 21505102)
1. Common and overlapping oncogenic pathways contribute to the evolution of acute myeloid leukemias.
Kvinlaug BT; Chan WI; Bullinger L; Ramaswami M; Sears C; Foster D; Lazic SE; Okabe R; Benner A; Lee BH; De Silva I; Valk PJ; Delwel R; Armstrong SA; Döhner H; Gilliland DG; Huntly BJ
Cancer Res; 2011 Jun; 71(12):4117-29. PubMed ID: 21505102
[TBL] [Abstract][Full Text] [Related]
2. Persistence of multipotent progenitors expressing AML1/ETO transcripts in long-term remission patients with t(8;21) acute myelogenous leukemia.
Miyamoto T; Nagafuji K; Akashi K; Harada M; Kyo T; Akashi T; Takenaka K; Mizuno S; Gondo H; Okamura T; Dohy H; Niho Y
Blood; 1996 Jun; 87(11):4789-96. PubMed ID: 8639850
[TBL] [Abstract][Full Text] [Related]
3. The acute myeloid leukemia associated AML1-ETO fusion protein alters the transcriptome and cellular progression in a single-oncogene expressing in vitro induced pluripotent stem cell based granulocyte differentiation model.
Tijchon E; Yi G; Mandoli A; Smits JGA; Ferrari F; Heuts BMH; Wijnen F; Kim B; Janssen-Megens EM; Schuringa JJ; Martens JHA
PLoS One; 2019; 14(12):e0226435. PubMed ID: 31869378
[TBL] [Abstract][Full Text] [Related]
4. POU4F1 is associated with t(8;21) acute myeloid leukemia and contributes directly to its unique transcriptional signature.
Fortier JM; Payton JE; Cahan P; Ley TJ; Walter MJ; Graubert TA
Leukemia; 2010 May; 24(5):950-7. PubMed ID: 20376082
[TBL] [Abstract][Full Text] [Related]
5. KRAS (G12D) cooperates with AML1/ETO to initiate a mouse model mimicking human acute myeloid leukemia.
Zhao S; Zhang Y; Sha K; Tang Q; Yang X; Yu C; Liu Z; Sun W; Cai L; Xu C; Cui S
Cell Physiol Biochem; 2014; 33(1):78-87. PubMed ID: 24480914
[TBL] [Abstract][Full Text] [Related]
6. NUP98-HOXA9 bearing therapy-related myeloid neoplasm involves myeloid-committed cell and induces HOXA5, EVI1, FLT3, and MEIS1 expression.
Burillo-Sanz S; Morales-Camacho RM; Caballero-Velázquez T; Vargas MT; García-Lozano JR; Falantes JF; Prats-Martín C; Bernal R; Pérez-Simón JA
Int J Lab Hematol; 2016 Feb; 38(1):64-71. PubMed ID: 26418229
[TBL] [Abstract][Full Text] [Related]
7. Supraphysiologic levels of the AML1-ETO isoform AE9a are essential for transformation.
Link KA; Lin S; Shrestha M; Bowman M; Wunderlich M; Bloomfield CD; Huang G; Mulloy JC
Proc Natl Acad Sci U S A; 2016 Aug; 113(32):9075-80. PubMed ID: 27457952
[TBL] [Abstract][Full Text] [Related]
8. Downregulation of RUNX1/CBFβ by MLL fusion proteins enhances hematopoietic stem cell self-renewal.
Zhao X; Chen A; Yan X; Zhang Y; He F; Hayashi Y; Dong Y; Rao Y; Li B; Conway RM; Maiques-Diaz A; Elf SE; Huang N; Zuber J; Xiao Z; Tse W; Tenen DG; Wang Q; Chen W; Mulloy JC; Nimer SD; Huang G
Blood; 2014 Mar; 123(11):1729-38. PubMed ID: 24449215
[TBL] [Abstract][Full Text] [Related]
9. Activated leukemic oncogenes AML1-ETO and c-kit: role in development of acute myeloid leukemia and current approaches for their inhibition.
Rulina AV; Spirin PV; Prassolov VS
Biochemistry (Mosc); 2010 Dec; 75(13):1650-66. PubMed ID: 21417999
[TBL] [Abstract][Full Text] [Related]
10. Proleukemic RUNX1 and CBFbeta mutations in the pathogenesis of acute leukemia.
Engel ME; Hiebert SW
Cancer Treat Res; 2010; 145():127-47. PubMed ID: 20306249
[TBL] [Abstract][Full Text] [Related]
11. In vitro transformation of primary human CD34+ cells by AML fusion oncogenes: early gene expression profiling reveals possible drug target in AML.
Abdul-Nabi AM; Yassin ER; Varghese N; Deshmukh H; Yaseen NR
PLoS One; 2010 Aug; 5(8):e12464. PubMed ID: 20805992
[TBL] [Abstract][Full Text] [Related]
12. Thrombopoietin/MPL participates in initiating and maintaining RUNX1-ETO acute myeloid leukemia via PI3K/AKT signaling.
Pulikkan JA; Madera D; Xue L; Bradley P; Landrette SF; Kuo YH; Abbas S; Zhu LJ; Valk P; Castilla LH
Blood; 2012 Jul; 120(4):868-79. PubMed ID: 22613795
[TBL] [Abstract][Full Text] [Related]
13. Translocation products in acute myeloid leukemia activate the Wnt signaling pathway in hematopoietic cells.
Müller-Tidow C; Steffen B; Cauvet T; Tickenbrock L; Ji P; Diederichs S; Sargin B; Köhler G; Stelljes M; Puccetti E; Ruthardt M; deVos S; Hiebert SW; Koeffler HP; Berdel WE; Serve H
Mol Cell Biol; 2004 Apr; 24(7):2890-904. PubMed ID: 15024077
[TBL] [Abstract][Full Text] [Related]
14. Immortalization of human AE pre-leukemia cells by hTERT allows leukemic transformation.
Lin S; Wei J; Wunderlich M; Chou FS; Mulloy JC
Oncotarget; 2016 Aug; 7(35):55939-55950. PubMed ID: 27509060
[TBL] [Abstract][Full Text] [Related]
15. Leukemogenic mechanisms and targets of a NUP98/HHEX fusion in acute myeloid leukemia.
Jankovic D; Gorello P; Liu T; Ehret S; La Starza R; Desjobert C; Baty F; Brutsche M; Jayaraman PS; Santoro A; Mecucci C; Schwaller J
Blood; 2008 Jun; 111(12):5672-82. PubMed ID: 18388181
[TBL] [Abstract][Full Text] [Related]
16. Elucidation of Novel Therapeutic Targets for Acute Myeloid Leukemias with
Yun JW; Bae YK; Cho SY; Koo H; Kim HJ; Nam DH; Kim SH; Chun S; Joo KM; Park WY
Int J Mol Sci; 2019 Apr; 20(7):. PubMed ID: 30959925
[TBL] [Abstract][Full Text] [Related]
17. Induction of acute myeloid leukemia in mice by the human leukemia-specific fusion gene NUP98-HOXD13 in concert with Meis1.
Pineault N; Buske C; Feuring-Buske M; Abramovich C; Rosten P; Hogge DE; Aplan PD; Humphries RK
Blood; 2003 Jun; 101(11):4529-38. PubMed ID: 12543865
[TBL] [Abstract][Full Text] [Related]
18. NRASG12V oncogene facilitates self-renewal in a murine model of acute myelogenous leukemia.
Sachs Z; LaRue RS; Nguyen HT; Sachs K; Noble KE; Mohd Hassan NA; Diaz-Flores E; Rathe SK; Sarver AL; Bendall SC; Ha NA; Diers MD; Nolan GP; Shannon KM; Largaespada DA
Blood; 2014 Nov; 124(22):3274-83. PubMed ID: 25316678
[TBL] [Abstract][Full Text] [Related]
19. The Hematopoietic Transcription Factors RUNX1 and ERG Prevent AML1-ETO Oncogene Overexpression and Onset of the Apoptosis Program in t(8;21) AMLs.
Mandoli A; Singh AA; Prange KHM; Tijchon E; Oerlemans M; Dirks R; Ter Huurne M; Wierenga ATJ; Janssen-Megens EM; Berentsen K; Sharifi N; Kim B; Matarese F; Nguyen LN; Hubner NC; Rao NA; van den Akker E; Altucci L; Vellenga E; Stunnenberg HG; Martens JHA
Cell Rep; 2016 Nov; 17(8):2087-2100. PubMed ID: 27851970
[TBL] [Abstract][Full Text] [Related]
20. Evi1 defines leukemia-initiating capacity and tyrosine kinase inhibitor resistance in chronic myeloid leukemia.
Sato T; Goyama S; Kataoka K; Nasu R; Tsuruta-Kishino T; Kagoya Y; Nukina A; Kumagai K; Kubota N; Nakagawa M; Arai S; Yoshimi A; Honda H; Kadowaki T; Kurokawa M
Oncogene; 2014 Oct; 33(42):5028-38. PubMed ID: 24747972
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
